Organon & Co. (OGN) Projected to Post Earnings on Thursday

Organon & Co. (NYSE:OGN) is projected to announce its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $0.92 per share and revenue of $1.59 billion for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Organon & Co. Stock Performance

NYSE:OGN opened at $15.32 on Thursday. The firm has a market cap of $3.94 billion, a PE ratio of 3.04, a P/E/G ratio of 0.87 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The firm has a 50 day simple moving average of $15.41 and a 200-day simple moving average of $17.79.

Wall Street Analysts Forecast Growth

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.